Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings...
Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings...
Pharmaloz宣佈與主要糖果品牌進行最終合同談判；新的合作伙伴關係可能到2025年底每年增加3500萬美元的營業收入，使總營業收入達到5000萬美元，預計淨收益爲800萬美元。2026年預計達到1000萬美元；目標是每年節省600萬美元……
Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026; Targets $6M Annual Savings Through Non-Core Operations Cost-Cutting Without Affecting Core Units
Pharmaloz 宣佈與主要糖果品牌進行最終合同談判；新的合作伙伴關係到 2025 年底可能每年增加 3500萬美元的營業收入，總營業收入將達到 5000萬美元，預計淨收益爲 800萬美元。2026 年的目標爲 1000萬美元；通過非核心業務的成本削減，目標是每年節省 600萬美元，而不會影響核心單元。
The Company will review on Thursday, December 12th, at 12:00 p.m. EST.
公司將於 12 月 12 日星期四中午 12:00 (EST) 進行審查。
GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives.
紐約花園城，2024 年 12 月 11 日 (全球新聞網絡) -- ProPhase Labs, Inc. (納斯達克:PRPH) ("ProPhase" 或 "公司")，一家下一代生物技術、基因組學和診斷公司，今天就幾個關鍵計劃提供了更新。
Securing Low-Interest Rate Financing from a Global Private Equity Fund
從全球股權投資基金獲得低利率融資
ProPhase has secured an agreement with a...
ProPhas...
登入免費觀看全文
登入/註冊